Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine–bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for patients with relapsed and refractory classic Hodgkin lymphoma (rrHL). However, the optimal conditioning regimen and GVHD prophylaxis for rrHL remain undetermined. The aim of this study was to investigate outcomes of allo-HSCT with a fludarabine plus bendamustine (FluBe) conditioning regimen and GVHD prophylaxis with posttransplantation cyclophosphamide (PTCY) in patients with rrHL. Methods: Allo-HSCT results in 58 adult patients with rrHL were analyzed retrospectively. Results: Three-year overall survival and event-free survival were 81% (95% CI 65–91) and 55% (95% CI 38–72), respectively. The cumulative incidence of relapse (CIR) at 3 years was 33% (95% CI 13–51). The cumulative incidence of aGVHD grade II–IV and severe aGVHD grade III–IV was 36% (95% CI 22–48) and 22% (95% CI 9–33), respectively. The cumulative incidence of cGVHD was 32% (95% CI 17–45), including moderate or severe cGVHD in 17% (95% CI 4–28). Patients who developed aGVHD after allo-HSCT had significantly lower CIR (24% vs 49%, p = 0.004). The use of PBSC as a graft source also significantly reduced CIR (4% vs 61%, p = 0.002). Conclusions: FluBe-PTCY allo-HSCT facilitates favorable outcomes, low toxicity, and mortality in rrHL.